Cost-effectiveness targeting CLL
Publikation: Bidrag til tidsskrift › Leder › Forskning › fagfællebedømt
Standard
Cost-effectiveness targeting CLL. / Niemann, Carsten Utoft.
I: Blood, Bind 136, Nr. 17, 2020, s. 1896-1898.Publikation: Bidrag til tidsskrift › Leder › Forskning › fagfællebedømt
Harvard
Niemann, CU 2020, 'Cost-effectiveness targeting CLL', Blood, bind 136, nr. 17, s. 1896-1898. https://doi.org/10.1182/blood.2020006949
APA
Niemann, C. U. (2020). Cost-effectiveness targeting CLL. Blood, 136(17), 1896-1898. https://doi.org/10.1182/blood.2020006949
Vancouver
Niemann CU. Cost-effectiveness targeting CLL. Blood. 2020;136(17):1896-1898. https://doi.org/10.1182/blood.2020006949
Author
Bibtex
@article{a188e048231141efb530c70131a3b973,
title = "Cost-effectiveness targeting CLL",
keywords = "Adenine/analogs & derivatives, Cost-Benefit Analysis, Humans, Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy, Piperidines, Pyrazoles, Pyrimidines",
author = "Niemann, {Carsten Utoft}",
year = "2020",
doi = "10.1182/blood.2020006949",
language = "English",
volume = "136",
pages = "1896--1898",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "17",
}
RIS
TY - JOUR
T1 - Cost-effectiveness targeting CLL
AU - Niemann, Carsten Utoft
PY - 2020
Y1 - 2020
KW - Adenine/analogs & derivatives
KW - Cost-Benefit Analysis
KW - Humans
KW - Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy
KW - Piperidines
KW - Pyrazoles
KW - Pyrimidines
U2 - 10.1182/blood.2020006949
DO - 10.1182/blood.2020006949
M3 - Editorial
C2 - 33091134
VL - 136
SP - 1896
EP - 1898
JO - Blood
JF - Blood
SN - 0006-4971
IS - 17
ER -
ID: 261535324